RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II TRIAL ASSESSING SAFETY OF TWO DIFFERENT DOSES OF SIMVASTATIN IN COMBINATION WITH RIFAXIMIN IN DECOMPENSATED CIRRHOSIS
暂无分享,去创建一个
R. Andrade | M. Bernardi | P. Kamath | J. Trebicka | F. Durand | P. Angeli | P. Caraceni | U. Beuers | P. Ginès | G. Zaccherini | J. Abraldes | E. Pose | G. Doménech | D. Campion | C. Alessandria | R. Mookerjee | J. Pich | S. Piano | O. Roux | E. Solà | L. Napoleone | Marta | M. Carol | A. Amin | F. Torres | J. Ferrero | César Jiménez | Frank Erhard | Uschner | K. Wit | V. Vargas | Llopis | Victor Vargas | P. Ginés
[1] N. Heaton,et al. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all‐cause admissions in patients on the liver transplant waiting list , 2019, Alimentary pharmacology & therapeutics.
[2] T. Taddei,et al. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. , 2019, Gastroenterology.
[3] J. Trebicka,et al. Statins: Old drugs as new therapy for liver diseases? , 2019, Journal of hepatology.
[4] J. Trebicka,et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. , 2018, Journal of hepatology.
[5] S. Sørensen,et al. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial , 2018, Journal of gastroenterology and hepatology.
[6] K. Das,et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study , 2018, European journal of gastroenterology & hepatology.
[7] J. Bosch,et al. Statins in cirrhosis—Ready for prime time , 2017, Hepatology.
[8] S. Kalko,et al. Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis , 2016, Scientific Reports.
[9] J. Bosch,et al. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. , 2016, Gastroenterology.
[10] M. Soldan,et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[11] H. Grønbæk,et al. Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites , 2015, Scandinavian journal of gastroenterology.
[12] G. Alexander,et al. Rifaximin is largely safe and well tolerated but caution is necessary when taken with statins. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[13] J. Talwalkar,et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. , 2014, Journal of hepatology.
[14] A. Sanyal,et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[15] Philip Wong,et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver , 2014, Hepatology.
[16] W. Haefeli,et al. CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores. , 2014, British journal of clinical pharmacology.
[17] R. Weaver,et al. ATP-dependent transport of statins by human and rat MRP2/Mrp2. , 2013, Toxicology and applied pharmacology.
[18] R. Moreau,et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. , 2013, Gastroenterology.
[19] A. Fotopoulos,et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[20] M. Molokhia,et al. Case Definition and Phenotype Standardization in Drug‐Induced Liver Injury , 2011, Clinical pharmacology and therapeutics.
[21] J. Bosch,et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. , 2009, Gastroenterology.
[22] R. Bataller,et al. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. , 2009, American journal of physiology. Gastrointestinal and liver physiology.
[23] R. Collins,et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.
[24] J. Armitage,et al. The safety of statins in clinical practice , 2007, The Lancet.
[25] W. Forbes,et al. The Effect of Multiple‐Dose, Oral Rifaximin on the Pharmacokinetics of Intravenous and Oral Midazolam in Healthy Volunteers , 2007, Pharmacotherapy.
[26] F. Nevens,et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho‐kinase and activation of endothelial nitric oxide synthase , 2007, Hepatology.
[27] Se-Ho Chang,et al. The Clinical Characteristics of Rhabdomyolysis in Patients With Liver Cirrhosis , 2007, Journal of clinical gastroenterology.
[28] A. P. Venturini. Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration. , 1983, Chemotherapy.